The new analysis, published in Annals of Hematology by a team led by researchers at the Children’s Hospital of Chongqing Medical University, pooled data from 83 studies covering 542 patients treated with ruxolitinib-based regimens. Because no randomized controlled trials have ever evaluated ruxolitinib in hemophagocytic lymphohistiocytosis, the investigators conducted a systematic review and single-arm meta-analysis, registered prospectively with PROSPERO under identifier CRD42025639580. Their headline finding: the pooled overall response rate was 87.2 percent, with a 95 percent confidence interval of 80.8 to 92.7 percent and moderate statistical heterogeneity. When the authors split the results by disease subtype, a clear divide emerged. Patients with primary, or familial, hemophagocytic lymphohistiocytosis—a genetic disorder of immune regulation—achieved a response rate of 100 percent in the pooled data, compared with 82.4 percent in secondary forms triggered by infections, malignancies, or autoimmune disease, a difference that was statistically significant.

Survival figures told a similar story in the short term. The pooled overall survival rate was 91.6 percent at two months, falling to 81.6 percent at six months and 73.9 percent at one year, reflecting the relentless attrition that characterizes this syndrome even under modern therapy. Again, the primary form showed an advantage: 100 percent survival at two months versus 87.7 percent in secondary disease. The authors emphasize that these estimates remained robust in sensitivity analyses that excluded individual case reports, which are often criticized for publication bias since clinicians tend to publish successes rather than failures. Of the 83 included studies, 27 were single-arm trials or cohort studies while 56 were case reports or series, making the exclusion analysis a critical test of whether the headline numbers were propped up by anecdote. They were not.

To understand why these results matter, it helps to understand what ruxolitinib actually does. The drug is an inhibitor of Janus kinases 1 and 2, enzymes that sit at the receiving end of signaling pathways used by many inflammatory cytokines, including interferon-gamma and interleukins that drive T-cell and macrophage activation. In hemophagocytic lymphohistiocytosis, hyperactivated CD8-positive T cells and macrophages flood the body with these cytokines, causing fever, spleen enlargement, falling blood counts, liver injury, and, in the worst cases, multi-organ failure. By dampening cytokine signaling at the intracellular level, ruxolitinib acts upstream of the cellular destruction, calming the storm rather than simply suppressing the immune system wholesale with cytotoxic chemotherapy. This mechanism is why hematologists began experimenting with it off-label in the most desperate cases—patients failing standard etoposide-based regimens, for instance, or infants with genetic disease awaiting stem cell transplantation.

The distinction between primary and secondary disease is central to the new findings. Primary hemophagocytic lymphohistiocytosis arises from inherited defects in genes governing the cytotoxic machinery of natural killer cells and CD8 T cells, such as perforin pathways, and historically it was almost always fatal in infancy without hematopoietic stem cell transplantation. Secondary, or acquired, forms erupt on top of infections like Epstein-Barr virus, malignancies, or autoimmune conditions, and their biology is more heterogeneous, reflecting diverse underlying triggers. The higher pooled response rate in the primary form may seem counterintuitive at first—genetic disease might be expected to be harder to treat—but it fits with the drug’s mechanism. In primary disease, the cytokine loop is driven by a relatively uniform defect in cytotoxic function, and blocking the downstream signaling amplifiers may interrupt the feedback circuit very effectively. Secondary disease, by contrast, is entangled with the underlying trigger: a lymphoma continues to grow, a viral infection persists, and ruxolitinib alone cannot remove the source of the inflammation. The authors also observed more frequent pancreatic injury and severe hematological toxicity in the primary group, hinting that treatment intensity or disease biology differs between the subtypes in ways that deserve dedicated study.

Safety data from the synthesis add important nuance for clinicians weighing the drug at the bedside. The most frequent adverse events across the pooled population were infections at 9.3 percent, neutropenia at 7.5 percent, and hepatic dysfunction at 7.0 percent. These figures are notable because they are modest for a drug used in critically ill, profoundly immunosuppressed patients, but they are not trivial. Ruxolitinib’s immunosuppressive mechanism raises a theoretical concern about reactivation of latent infections, and cytomegalovirus reactivation in particular has been reported in clinical experience with the drug. The analysis does not settle that question definitively, and the authors are candid that rare disease research carries inherent limitations: no randomized comparisons, heterogeneous dosing and combination regimens, variable definitions of response across studies, and follow-up that is often short in a syndrome where patients may die quickly or be rescued by transplantation.

Those caveats frame the study’s real contribution. By aggregating every available strand of evidence—trials, cohorts, and hundreds of individually reported cases—the analysis provides the first quantitative benchmark for what clinicians can realistically expect from ruxolitinib-based therapy in each subtype. An 87 percent pooled response rate across the spectrum, with survival above 90 percent at two months, is a signal strong enough to inform practice today and to shape the design of the trials that must follow. The subgroup difference is arguably the most actionable finding: it suggests that in secondary hemophagocytic lymphohistiocytosis, ruxolitinib should probably be positioned as part of a strategy that simultaneously attacks the underlying trigger, whether that is antiviral therapy, chemotherapy for lymphoma, or immunosuppression for autoimmune disease, rather than as monotherapy expected to carry the patient alone.

The authors, led by Zirui Ding with senior authorship from Xi Yang, Xiaodong Zhao, and Ximing Xu among a team spanning Chongqing and Tokyo, including Hirokazu Kanegane of Institute of Science Tokyo, write that their findings provide critical guidance for clinical practice and future trial design despite the limitations inherent in studying a rare disease. The research was supported by grants from Chongqing municipal health and science funding programs, and the work reflects the growing capacity of pediatric immunology and hematology centers in China to mount large evidence syntheses in ultra-rare conditions where no single institution sees enough patients to study them alone.

For the rare disease community, the study lands at a moment of genuine momentum. Ruxolitinib has already been tested in randomized trials for graft-versus-host disease and is approved for several myeloproliferative neoplasms, giving physicians extensive familiarity with its dosing and toxicity profile. The new meta-analysis extends that familiarity into one of hematology’s most lethal emergencies, and its subtype-specific numbers give trial designers a clear benchmark against which future randomized studies of ruxolitinib in primary and secondary disease can be powered. What remains to be shown is whether the dramatic early responses translate into durable cures, particularly for patients with genetic disease who ultimately need stem cell transplantation, and whether the drug’s benefit in secondary forms depends critically on how aggressively the underlying trigger is treated alongside it. Those answers will require the very trials this synthesis is designed to enable.

Subject of Research: Efficacy and safety of the JAK1/JAK2 inhibitor ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis

Article Title: Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis

Article References: Ding, Z., Zhang, Z., Dou, Y., Jia, Y., An, Y., Tang, X., Kanegane, H., Xu, X., Zhao, X., & Yang, X. (2026). Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07274-9

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07274-9

Keywords: hemophagocytic lymphohistiocytosis, ruxolitinib, JAK1/JAK2 inhibitor, meta-analysis, primary HLH, secondary HLH, overall response rate, overall survival, adverse events, rare disease, immunotherapy, hematology